Workflow
ICON plc(ICLR)
icon
Search documents
Icon PLC (ICLR) Beats Q1 Earnings and Revenue Estimates
Zacks Investment Research· 2024-04-24 22:56
Icon PLC (ICLR) came out with quarterly earnings of $3.47 per share, beating the Zacks Consensus Estimate of $3.44 per share. This compares to earnings of $2.90 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 0.87%. A quarter ago, it was expected that this contract research organization would post earnings of $3.44 per share when it actually produced earnings of $3.46, delivering a surprise of 0.58%.Over the last four quarters ...
ICON (ICLR) Gains From New Offerings, Strategic Acquisitions
Zacks Investment Research· 2024-04-18 15:41
ICON plc’s (ICLR) focus on Patient Access & Engagement strategy and favorable CRO industry trends are major tailwinds. Strategic partnerships are an added positive. The stock carries a Zacks Rank #2 (Buy) currently.ICON is gaining from its focused patient, site and data strategy, which is helping it to improve site identification and study placement, patient recruitment and retention. In this regard, Accellacare, ICON's global clinical research network, is successfully offering customers a wide range of sta ...
ICON plc(ICLR) - 2023 Q4 - Annual Report
2024-02-23 21:39
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 ______________________________________________________________________ FORM 20-F (Mark One) ☐ Registration statement pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 OR ☒ Annual report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2023 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 OR ☐ Shell company rep ...
ICON plc(ICLR) - 2024 Q1 - Quarterly Report
2024-02-21 21:31
Exhibit 99.1 ICON Reports Fourth Quarter and Full Year 2023 Results Highlights Dublin, Ireland, February 21, 2024 – ICON plc (NASDAQ: ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the fourth quarter and year ended December 31, 2023. CEO, Dr. Steve Cutler commented, "With our focus on delivering innovative clinical development solutions, ICON's solid performance in quarter four and the full year 2023 reflects continued market leade ...
ICON plc(ICLR) - 2023 Q3 - Quarterly Report
2023-10-27 12:21
FORM 6-K SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Report of Foreign Private Issuer Pursuant to Rule 13a-16 under the Securities Exchange Act of 1934 For the month of October, 2023 ICON plc (Translation of registrant's name into English) 333-08704 (Commission file number) South County Business Park, Leopardstown, Dublin 18, D18 X5R3, Ireland (Address of principal executive offices) Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 4 ...
ICON plc(ICLR) - 2023 Q2 - Quarterly Report
2023-07-26 20:30
Revenue Performance - ICON reported second quarter 2023 revenue of $2,020.3 million, representing a year-over-year increase of 4.4%[5] - Year-to-date revenue reached $3,998.8 million, reflecting a year-over-year increase of 4.2%[10] - The company revised its full-year 2023 revenue guidance to a range of $8,070 - $8,210 million, indicating a growth of 4.3% to 6.1% year-over-year[4] Profitability Metrics - Adjusted EBITDA for the second quarter was $414.2 million, accounting for 20.5% of revenue, with a year-over-year growth of 16.9%[7] - Adjusted net income for the second quarter was $256.9 million, leading to an adjusted diluted earnings per share of $3.11, an increase of 8.7% from the prior year[7] - Adjusted EBITDA for the six months ended June 30, 2023, was $813,369 thousand, up from $694,910 thousand in the same period of 2022, reflecting an increase of 17.0%[28] - Adjusted net income attributable to the Group for the six months ended June 30, 2023, was $496,742 thousand, compared to $463,746 thousand in the same period of 2022, an increase of 7.1%[28] - Adjusted diluted net income per Ordinary Share attributable to the Group for the six months ended June 30, 2023, was $6.01, up from $5.62 in the same period of 2022, an increase of 6.9%[28] Cash Flow and Capital Expenditures - Cash generated from operating activities for the quarter was $203.9 million, with capital expenditures of $32.1 million[9] - Cash flows from operating activities for the six months ended June 30, 2023, were $379,381 thousand, compared to $408,966 thousand for the same period in 2022, indicating a decrease of 7.2%[26] - The company reported a net cash used in investing activities of $68,653 thousand for the six months ended June 30, 2023, compared to $48,639 thousand in the same period of 2022, an increase of 41.2%[26] - Cash and cash equivalents at the end of the period on June 30, 2023, were $270,176 thousand, down from $614,918 thousand at the end of the same period in 2022, a decrease of 56.1%[26] Business Wins and Backlog - The company achieved net business wins of $2,419 million in the second quarter, resulting in a book-to-bill ratio of 1.20[6] - The closing backlog increased to $21.7 billion, up 2.2% from the first quarter of 2023 and 8.5% from the second quarter of 2022[5] Debt and Taxation - The net debt balance stood at $4.0 billion, with a net debt to adjusted EBITDA ratio of 2.5x[5] - The effective tax rate for the second quarter was 15.2%, with an updated estimate for the full-year 2023 effective tax rate at 15.5%[8] Shareholder Information - The diluted weighted average number of Ordinary Shares outstanding for the six months ended June 30, 2023, was 82,617,391, compared to 82,462,842 for the same period in 2022[28] Acquisitions - The company completed the acquisition of a 51% majority voting share capital of Oncacare Limited, resulting in an acquisition-related gain of $6,160 thousand[33] Overall Income - Net income for the six months ended June 30, 2023, was $232,252 thousand, a slight increase from $227,704 thousand in the same period of 2022, representing a growth of 2.4%[26] - Total liabilities and equity as of June 30, 2023, were $17,107,660 thousand, a decrease from $17,185,278 thousand as of the previous period[23]
ICON plc(ICLR) - 2023 Q1 - Earnings Call Transcript
2023-04-27 18:22
ICON Public Limited Company (NASDAQ:ICLR) Q1 2023 Earnings Conference Call April 27, 2023 8:00 AM ET Company Participants Kate Haven - VP of IR Steve Cutler - CEO Brendan Brennan - CFO Conference Call Participants John Sourbeer - UBS Ann Hynes - Mizuho Group Elizabeth Anderson - Evercore ISI Max Smock - William Blair Patrick Donnelly - Citi Eric Coldwell - R. W. Baird Sandy Draper - Guggenheim and Partner David Windley - Jefferies Justin Bowers - Deutsche Bank Luke Sergott - Barclays Casey Woodring - JPMorg ...
ICON plc(ICLR) - 2022 Q4 - Annual Report
2023-02-24 21:34
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C.20549 ______________________________________________________________________ FORM 20-F (Mark One) ☐ Registration statement pursuant to Section 12(b) or (g) of the Securities Exchange Act of 1934 OR ☒ Annual report pursuant to Section 13 or 15 (d) of the Securities Exchange Act of 1934 For the fiscal year ended: December 31, 2022 OR ☐ Transition report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 OR ☐ Shell company rep ...
ICON plc(ICLR) - 2022 Q4 - Earnings Call Transcript
2023-02-23 17:19
ICON Public Limited Company (NASDAQ:ICLR) Q4 2022 Earnings Conference Call February 23, 2023 8:00 AM ET Company Participants Kate Haven - VP of IR Brendan Brennan - CFO Steve Cutler - CEO Conference Call Participants Sandy Draper - Guggenheim Justin Bowers - Deutsche Bank Patrick Donnelly - Citi Eric Coldwell - Baird Casey Woodring - JPMorgan David Windley - Jefferies Elizabeth Anderson - Evercore Dan Leonard - Credit Suisse Jack Meehan - Nephron Research Derik De Bruin - Bank of America Operator Good day a ...
ICON plc(ICLR) - 2023 Q1 - Quarterly Report
2023-02-22 21:47
Exhibit 99.1 ICON Reports Fourth Quarter and Full Year 2022 Results CEO, Dr. Steve Cutler commented, "ICON continued its positive momentum in the fourth quarter of 2022, with 7.6% constant currency revenue growth year over year, and delivering on our full-year financial outlook in a dynamic market environment. We saw solid demand across our portfolio of services, resulting in backlog growth of 8.7% on a year over year basis. The combination of strong underlying operational performance and focused cost manag ...